December 2, 2020
Takeda Pharmaceutical said on December 1 that it has completed the sale of 18 select non-core OTC and prescription drugs sold exclusively in Asia Pacific to South Korea’s Celltrion for US$278 million including milestones. The divested products include medicines in...read more